MX2019003821A - Composiciones de aminoacidos y usos de las mismas. - Google Patents

Composiciones de aminoacidos y usos de las mismas.

Info

Publication number
MX2019003821A
MX2019003821A MX2019003821A MX2019003821A MX2019003821A MX 2019003821 A MX2019003821 A MX 2019003821A MX 2019003821 A MX2019003821 A MX 2019003821A MX 2019003821 A MX2019003821 A MX 2019003821A MX 2019003821 A MX2019003821 A MX 2019003821A
Authority
MX
Mexico
Prior art keywords
vivo
treating
differentiation
present disclosure
proliferation
Prior art date
Application number
MX2019003821A
Other languages
English (en)
Inventor
Vidyasagar Sadasivan
Gupta Reshu
Yin Lianjie
Grosche Astrid
Gerson Okunieff Paul
Gatto Stephen
Dennison Daniel
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2019003821A publication Critical patent/MX2019003821A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona composiciones y métodos para promover la proliferación y/o diferenciación de células madre y/o progenitoras. Las composiciones proporcionadas pueden ser útiles en el tratamiento de una enfermedad o afecciones relacionadas con la función de barrera de la mucosa, por ejemplo, la cicatrización de heridas, el tratamiento de afecciones de la piel (por ejemplo, dermatitis atópica, psoriasis, úlceras de decúbito o afecciones relacionadas con el envejecimiento de la piel), el tratamiento de trastomos pulmonares (por ejemplo, asma), una afección relacionada con la mejora de la función de barrera mucosa, y/o el tratamiento de lesiones de la mucosa gastrointestinal en un sujeto que lo necesite. La presente divulgación también proporciona métodos para promover la proliferación y/o diferenciación de células madre y/o las células progenitoras en un sujeto que necesita tal tratamiento mediante la administración de una composición. La capacidad de estimular la proliferación y/o diferenciación de las células madre y/o las células progenitoras in vivo, ex vivo y/o in vitro proporciona un gran beneficio. La presente divulgación puede ser utilizada para aumentar las poblaciones de células madre in vivo, ex vivo y/o in vitro. El trasplante de células madre proporciona tratamientos y/o curas de muchos estados de enfermedad, degeneración y/o lesión.
MX2019003821A 2016-10-04 2017-10-04 Composiciones de aminoacidos y usos de las mismas. MX2019003821A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403965P 2016-10-04 2016-10-04
US201662421443P 2016-11-14 2016-11-14
PCT/US2017/055167 WO2018067717A1 (en) 2016-10-04 2017-10-04 Amino acid compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2019003821A true MX2019003821A (es) 2019-12-18

Family

ID=61831937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003821A MX2019003821A (es) 2016-10-04 2017-10-04 Composiciones de aminoacidos y usos de las mismas.

Country Status (9)

Country Link
US (1) US11576884B2 (es)
EP (1) EP3522882A4 (es)
JP (2) JP7267546B2 (es)
CN (2) CN115645388A (es)
AU (1) AU2017338887B2 (es)
BR (1) BR112019006742A2 (es)
CA (2) CA3039514C (es)
MX (1) MX2019003821A (es)
WO (1) WO2018067717A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993522B2 (en) 2010-09-24 2015-03-31 University Of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
MX361647B (es) 2013-03-11 2018-12-13 Univ Florida Materiales y métodos para mejorar la función pulmonar y para la prevención y/o tratamiento de complicaciones pulmonares inducidas por radiación.
BR112020020318A2 (pt) * 2018-04-04 2021-01-05 University Of Florida Research Foundation, Incorporated Composições para tratamento de pele
US20210212973A1 (en) * 2018-07-30 2021-07-15 Almeda Labs Llc Cardioprotective amino acid formulation
RU2709502C1 (ru) * 2019-09-23 2019-12-18 Виктор Александрович Сисев Фармацевтическая композиция для парентерального капельного введения
AU2021207295A1 (en) * 2020-01-13 2022-08-04 Monash University Compositions and methods
JP7470376B2 (ja) 2020-03-31 2024-04-18 国立大学法人山口大学 顎下腺の萎縮抑制剤及び創傷治癒促進剤
EP4175662A1 (en) * 2020-07-02 2023-05-10 University Of Florida Research Foundation, Incorporated Formulations for promoting hydration and methods of use thereof
CN114097952A (zh) * 2020-08-28 2022-03-01 河北科星药业有限公司 毛丝鼠专用的营养添加剂、其制备方法及应用
WO2023130094A2 (en) * 2022-01-03 2023-07-06 Entrinsic, LLC Formulations and methods for skin care
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430303T2 (de) 1991-03-05 2002-11-28 Aradigm Corp Verfahren und vorrichtung zur korrektur eines nullsignals eines drucksensors fur einen durchflussmesser
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP0810829B1 (en) 1995-02-23 2000-04-12 Novartis Nutrition AG Amino acid compositions and use thereof in clinical nutrition
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
MXPA01002875A (es) 1998-11-13 2002-04-08 Los Angeles Childrens Hospital Metodos para facilitar el crecimiento vascular.
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
CA2557814A1 (en) 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US20070010459A1 (en) 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
DK2164349T3 (en) * 2006-08-04 2014-12-15 Shs Int Ltd protein-FORMULA
US20110183040A1 (en) * 2007-08-03 2011-07-28 Ermolin Gennady A Amino Acid and Peptide Products
JP5576097B2 (ja) 2009-11-17 2014-08-20 大塚製薬株式会社 気道抵抗改善剤
IT1396935B1 (it) 2009-11-26 2012-12-20 Solartium Entpr Ltd Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
IT1397023B1 (it) 2009-11-27 2012-12-20 Professional Dietetics Srl Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
KR20120113259A (ko) 2010-01-08 2012-10-12 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 생물막의 처리에서 사용하기 위한 ｄ-아미노산
US8993522B2 (en) 2010-09-24 2015-03-31 University Of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
JP2012214451A (ja) * 2011-03-25 2012-11-08 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用アミノ酸組成物
EP2793813A1 (en) 2011-12-21 2014-10-29 Motolese, Pasquale Cosmetic composition and uses thereof in the treatment of lipodystrophies
US20140377374A1 (en) 2012-02-08 2014-12-25 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
MX361647B (es) * 2013-03-11 2018-12-13 Univ Florida Materiales y métodos para mejorar la función pulmonar y para la prevención y/o tratamiento de complicaciones pulmonares inducidas por radiación.
DE102013224993A1 (de) 2013-12-05 2015-06-11 Henkel Ag & Co. Kgaa Haarbehandlungsmittel mit substituierten Silikon(en)
US10413528B2 (en) 2014-10-20 2019-09-17 John H. Plumb Methods to inhibit infection during wound healing with topical compositions including amino acids
EP3616689A1 (en) 2014-11-24 2020-03-04 Entrinsic Health Solutions, Inc. Amino acid compositions for the treatment of symptoms of disease

Also Published As

Publication number Publication date
EP3522882A4 (en) 2020-06-24
CA3135553C (en) 2024-05-21
CA3135553A1 (en) 2018-04-12
CN115645388A (zh) 2023-01-31
WO2018067717A1 (en) 2018-04-12
JP2023100617A (ja) 2023-07-19
US20210283081A1 (en) 2021-09-16
US11576884B2 (en) 2023-02-14
AU2017338887B2 (en) 2020-09-03
CA3039514A1 (en) 2018-04-12
EP3522882A1 (en) 2019-08-14
AU2017338887A1 (en) 2019-05-02
CN110062621A (zh) 2019-07-26
CA3039514C (en) 2022-01-25
CN110062621B (zh) 2022-11-01
JP7267546B2 (ja) 2023-05-02
JP2019530750A (ja) 2019-10-24
BR112019006742A2 (pt) 2019-09-03

Similar Documents

Publication Publication Date Title
MX2019003821A (es) Composiciones de aminoacidos y usos de las mismas.
Mehler Medical complications of bulimia nervosa and their treatments.
WO2019094642A8 (en) T cell manufacturing compositions and methods
WO2012065027A3 (en) Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
AR081450A1 (es) Tratamiento de sarcoidosis usando celulas madre de placenta
NZ602777A (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EA201490697A1 (ru) Белки с двойной функцией для лечения метаболических расстройств
FR2969495B1 (fr) Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant
CN105193672B (zh) 一种细胞再生元修复精华液及其制备方法
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
EP3818991A3 (en) Compositions and methods for treating diseases
Palm et al. Transcranial random noise stimulation for the treatment of negative symptoms in schizophrenia.
RU2014150505A (ru) Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
MX2017005186A (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
AR096594A1 (es) Tetrapéptidos derivados de quimioquinas c-x-c humanas útiles para tratar diversas afecciones en la piel
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2021002017A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
NZ629964A (en) Method for treating inflammation
MX2009004962A (es) Metodo para tratar asma, rinitis alergia y trastornos de la piel.
MY197917A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
WO2011139246A8 (en) Topical or injectable composition comprising humic acid salts and polyvinylpyrrolidone for the treatment of skin diseases
CN106902011A (zh) 一种中药消炎祛痘面膜
CN105521015A (zh) 一种治疗脚气的中药配方